In an SEC filing, AbbVie ABBV has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per ...
AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...
RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma (the "Company" or "RyCarma"), a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and ...
AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $25.00. Discover the latest stocks recommended by ...
Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) and keeping the price target at $30.00. Discover the latest stocks ...
C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions ...
TECELRA is the first engineered cell therapy for a soli Adaptimmune Therapeutics PLC (ADAP) outlines a path to operating breakeven by 2027, driven by strategic restructuring and promising outcomes ...